| D003131 |
Combined Modality Therapy |
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. |
Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal |
|
| D003937 |
Diagnosis, Differential |
Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. |
Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis |
|
| D005260 |
Female |
|
Females |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000328 |
Adult |
A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. |
Adults |
|
| D012468 |
Salivary Gland Neoplasms |
Tumors or cancer of the SALIVARY GLANDS. |
Cancer of Salivary Gland,Non-Sebaceous Lymphadenomas,Salivary Gland Cancer,Salivary Gland Lymphadenomas,Sebaceous Lymphadenomas,Cancer of the Salivary Gland,Neoplasms, Salivary Gland,Cancer, Salivary Gland,Cancers, Salivary Gland,Gland Neoplasm, Salivary,Gland Neoplasms, Salivary,Lymphadenoma, Non-Sebaceous,Lymphadenoma, Salivary Gland,Lymphadenoma, Sebaceous,Lymphadenomas, Non-Sebaceous,Lymphadenomas, Salivary Gland,Lymphadenomas, Sebaceous,Neoplasm, Salivary Gland,Non Sebaceous Lymphadenomas,Non-Sebaceous Lymphadenoma,Salivary Gland Cancers,Salivary Gland Lymphadenoma,Salivary Gland Neoplasm,Sebaceous Lymphadenoma |
|
| D016896 |
Treatment Outcome |
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. |
Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes |
|
| D018267 |
Carcinoma, Acinar Cell |
A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575) |
Acinar Carcinoma,Acinar Cell Adenocarcinoma,Acinic Cell Adenocarcinoma,Acinic Cell Carcinoma,Acinic Cell Tumor,Serous Acinar Adenoma,Acinar Carcinomas,Acinar Cell Adenocarcinomas,Acinar Cell Carcinoma,Acinar Cell Carcinomas,Acinic Cell Adenocarcinomas,Acinic Cell Carcinomas,Acinic Cell Tumors,Adenocarcinoma, Acinar Cell,Adenocarcinoma, Acinic Cell,Adenocarcinomas, Acinar Cell,Adenocarcinomas, Acinic Cell,Carcinoma, Acinar,Carcinoma, Acinic Cell,Carcinomas, Acinar,Carcinomas, Acinar Cell,Carcinomas, Acinic Cell,Tumor, Acinic Cell,Tumors, Acinic Cell |
|